Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer

Bibliographic Details
Title: Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer
Authors: Feizhi Lin, Yongming Chen, Bowen Huang, Shenghang Ruan, Jun Lin, Zewei Chen, Chunyu Huang, Baiwei Zhao
Source: Frontiers in Pharmacology, Vol 15 (2024)
Publisher Information: Frontiers Media S.A., 2024.
Publication Year: 2024
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: perioperative treatment, gastric cancer, immunotherapy, neoadjuvant therapy, adjuvant therapy, chemotherapy, Therapeutics. Pharmacology, RM1-950
More Details: Gastric/gastroesophageal junction (G/GEJ) cancer represents a significant global health challenge. Radical surgery remains the cornerstone of treatment for resectable G/GEJ cancer. Supported by robust evidence from multiple clinical studies, therapeutic approaches, including adjuvant chemotherapy or chemoradiation, and perioperative chemotherapy, are generally recommended to reduce the risk of recurrence and enhance long-term survival outcomes post-surgery. In recent years, immune checkpoint inhibitors (ICIs) have altered the landscape of systemic treatment for advanced or metastatic G/GEJ cancer, becoming the standard first-line therapy for specific patients. Consequently, exploring the efficacy of ICIs in the adjuvant or neoadjuvant setting for resectable G/GEJ cancer is worthwhile. This review summarizes the current advances in the application of ICIs for resectable G/GEJ cancer.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1663-9812
Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1391562/full; https://doaj.org/toc/1663-9812
DOI: 10.3389/fphar.2024.1391562
Access URL: https://doaj.org/article/6c08046cccef4fc3bec2a8c16060a70e
Accession Number: edsdoj.6c08046cccef4fc3bec2a8c16060a70e
Database: Directory of Open Access Journals